Do analysts recommend RDHL or DARE?

Dare Bioscience has a consensus target price of $6.50, suggesting a potential upside of 692.68%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts rate SCNX or RDHL?

Scienture currently has a consensus target price of $1.50, suggesting a potential upside of 435.71%. Given Scienture's stronger consensus rating and higher probable upside, analysts clearly believe Scienture is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNX or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -53.51% -42.47% Redhill Biopharma N/A N/A N/A

Is QNRX or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Quoin Pharmaceuticals N/A -489.57% -221.17% Redhill Biopharma N/A N/A N/A

Do analysts recommend PBM or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PBM or RDHL more profitable?

Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Redhill Biopharma N/A N/A N/A

Do analysts prefer CALC or RDHL?

CalciMedica presently has a consensus price target of $50.00, suggesting a potential upside of 2,732.86%. Given CalciMedica's stronger consensus rating and higher possible upside, research analysts clearly believe CalciMedica is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CALC or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -155.24% Redhill Biopharma N/A N/A N/A

Redhill Biopharma (RDHL) Competitors

$0.56 +0.02 (+3.11%)

As of 09:39 AM Eastern

Compare

RDHL vs. DARE, SCNX, QNRX, PBM, and CALC

Should you buy Redhill Biopharma stock or one of its competitors? Redhill Biopharma's main competitors and comparable companies include Dare Bioscience (DARE), Scienture (SCNX), Quoin Pharmaceuticals (QNRX), Psyence Biomedical (PBM), and CalciMedica (CALC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Redhill Biopharma compare to Dare Bioscience?

Redhill Biopharma (NASDAQ:RDHL) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Redhill Biopharma has a beta of 4.96, meaning that its stock price is 396% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Redhill Biopharma has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	11.74	-$430K	$900.00	0.00
Dare Bioscience	$1.03M	15.66	-$13.40M	-$0.70	N/A

In the previous week, Redhill Biopharma's average media sentiment score of 0.00 equaled Dare Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Dare Bioscience	Neutral

Dare Bioscience has a consensus target price of $6.50, suggesting a potential upside of 692.68%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Redhill Biopharma has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Redhill Biopharma's return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Dare Bioscience	-803.80%	-748.30%	-38.75%

Summary

Redhill Biopharma beats Dare Bioscience on 9 of the 14 factors compared between the two stocks.

How does Redhill Biopharma compare to Scienture?

Scienture (NASDAQ:SCNX) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

In the previous week, Scienture had 3 more articles in the media than Redhill Biopharma. MarketBeat recorded 3 mentions for Scienture and 0 mentions for Redhill Biopharma. Scienture's average media sentiment score of 0.06 beat Redhill Biopharma's score of 0.00 indicating that Scienture is being referred to more favorably in the media.

Company	Overall Sentiment
Scienture	Neutral
Redhill Biopharma	Neutral

Redhill Biopharma has lower revenue, but higher earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	26.74	-$41.51M	-$2.10	N/A
Redhill Biopharma	$290K	11.74	-$430K	$900.00	0.00

Redhill Biopharma's return on equity of 0.00% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Redhill Biopharma	N/A	N/A	N/A

5.7% of Scienture shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 21.4% of Scienture shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Scienture has a beta of 3.25, suggesting that its stock price is 225% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.96, suggesting that its stock price is 396% more volatile than the broader market.

Scienture currently has a consensus target price of $1.50, suggesting a potential upside of 435.71%. Given Scienture's stronger consensus rating and higher probable upside, analysts clearly believe Scienture is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Scienture beats Redhill Biopharma on 8 of the 15 factors compared between the two stocks.

How does Redhill Biopharma compare to Quoin Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Redhill Biopharma's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%
Redhill Biopharma	N/A	N/A	N/A

Quoin Pharmaceuticals has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.96, suggesting that its stock price is 396% more volatile than the broader market.

Redhill Biopharma has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A
Redhill Biopharma	$290K	11.74	-$430K	$900.00	0.00

Quoin Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 187.81%. Given Quoin Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Quoin Pharmaceuticals is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Quoin Pharmaceuticals had 4 more articles in the media than Redhill Biopharma. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 0 mentions for Redhill Biopharma. Quoin Pharmaceuticals' average media sentiment score of 0.25 beat Redhill Biopharma's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Quoin Pharmaceuticals	Neutral
Redhill Biopharma	Neutral

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 11.2% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Quoin Pharmaceuticals and Redhill Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Redhill Biopharma compare to Psyence Biomedical?

Psyence Biomedical (NASDAQ:PBM) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Redhill Biopharma has higher revenue and earnings than Psyence Biomedical. Redhill Biopharma is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.25
Redhill Biopharma	$290K	11.74	-$430K	$900.00	0.00

In the previous week, Psyence Biomedical had 5 more articles in the media than Redhill Biopharma. MarketBeat recorded 5 mentions for Psyence Biomedical and 0 mentions for Redhill Biopharma. Psyence Biomedical's average media sentiment score of 0.41 beat Redhill Biopharma's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Neutral
Redhill Biopharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Redhill Biopharma	N/A	N/A	N/A

Psyence Biomedical has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.96, meaning that its stock price is 396% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Redhill Biopharma beats Psyence Biomedical on 5 of the 9 factors compared between the two stocks.

How does Redhill Biopharma compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

CalciMedica has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.96, indicating that its share price is 396% more volatile than the broader market.

In the previous week, CalciMedica's average media sentiment score of 0.00 equaled Redhill Biopharma'saverage media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
Redhill Biopharma	Neutral

Redhill Biopharma's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
Redhill Biopharma	N/A	N/A	N/A

7.2% of Redhill Biopharma shares are held by institutional investors. 28.3% of CalciMedica shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

CalciMedica presently has a consensus price target of $50.00, suggesting a potential upside of 2,732.86%. Given CalciMedica's stronger consensus rating and higher possible upside, research analysts clearly believe CalciMedica is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$6.80	N/A
Redhill Biopharma	$290K	11.74	-$430K	$900.00	0.00

Summary

Redhill Biopharma beats CalciMedica on 8 of the 12 factors compared between the two stocks.

Get Redhill Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDHL vs. The Competition

Export

Metric	Redhill Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.41M	$12.59B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.56%
P/E Ratio	0.00	792.28	274.07	25.70
Price / Sales	11.74	857.34	673.22	90.62
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.67	10.58	10.38	6.32
Net Income	-$430K	$2.81B	$3.49B	$359.73M
7 Day Performance	-5.53%	-0.16%	-0.69%	0.17%
1 Month Performance	-7.47%	-1.38%	-3.19%	-3.27%
1 Year Performance	-66.47%	2.83%	15.12%	5.58%

Redhill Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDHL Redhill Biopharma	1.1431 of 5 stars	$0.56 +3.1%	N/A	-66.5%	$3.41M	$290K	0.00	210	Gap Down
DARE Dare Bioscience	2.4233 of 5 stars	$0.73 -0.8%	$6.50 +790.3%	-60.8%	$14.48M	$1.03M	N/A	30
SCNX Scienture	2.9535 of 5 stars	$0.33 -2.2%	$1.50 +352.5%	-66.3%	$13.92M	$430K	N/A	N/A	Analyst Forecast
QNRX Quoin Pharmaceuticals	3.5565 of 5 stars	$6.80 -1.2%	N/A	-5.9%	$13.82M	N/A	N/A	4	Analyst Forecast
PBM Psyence Biomedical	1.3178 of 5 stars	$6.07 +1.2%	N/A	-72.0%	$13.76M	N/A	0.24	N/A	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RDHL) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Redhill Biopharma (RDHL) Competitors

RDHL vs. DARE, SCNX, QNRX, PBM, and CALC

How does Redhill Biopharma compare to Dare Bioscience?

Summary

How does Redhill Biopharma compare to Scienture?

Summary

How does Redhill Biopharma compare to Quoin Pharmaceuticals?

Summary

How does Redhill Biopharma compare to Psyence Biomedical?

Summary

How does Redhill Biopharma compare to CalciMedica?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Redhill Biopharma (RDHL) Competitors

RDHL vs. DARE, SCNX, QNRX, PBM, and CALC

How does Redhill Biopharma compare to Dare Bioscience?

Which has more volatility & risk, RDHL or DARE?

Do insiders & institutionals hold more shares of RDHL or DARE?

Which has preferable earnings and valuation, RDHL or DARE?

Does the media refer more to RDHL or DARE?

Do analysts recommend RDHL or DARE?

Is RDHL or DARE more profitable?

Summary

How does Redhill Biopharma compare to Scienture?

Does the media prefer SCNX or RDHL?

Which has higher earnings and valuation, SCNX or RDHL?

Is SCNX or RDHL more profitable?

Do institutionals & insiders hold more shares of SCNX or RDHL?

Which has more risk and volatility, SCNX or RDHL?

Do analysts rate SCNX or RDHL?

Summary

How does Redhill Biopharma compare to Quoin Pharmaceuticals?

Is QNRX or RDHL more profitable?

Which has more risk and volatility, QNRX or RDHL?

Which has stronger valuation & earnings, QNRX or RDHL?

Do analysts prefer QNRX or RDHL?

Does the media favor QNRX or RDHL?

Do institutionals and insiders have more ownership in QNRX or RDHL?

Summary

How does Redhill Biopharma compare to Psyence Biomedical?

Which has higher earnings & valuation, PBM or RDHL?

Does the media favor PBM or RDHL?

Is PBM or RDHL more profitable?

Which has more volatility and risk, PBM or RDHL?

Do analysts recommend PBM or RDHL?

Do insiders & institutionals have more ownership in PBM or RDHL?

Summary

How does Redhill Biopharma compare to CalciMedica?

Which has more volatility and risk, CALC or RDHL?

Does the media favor CALC or RDHL?

Is CALC or RDHL more profitable?

Do institutionals & insiders hold more shares of CALC or RDHL?

Do analysts prefer CALC or RDHL?

Which has preferable earnings and valuation, CALC or RDHL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools